GF/B50/DP06
Approved by the Board on: 15 November 2023
Amended and Restated Global Fund Quality Assurance Policy for Pharmaceutical Products and Amended and Restated Global Fund Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment
Based on the recommendation of the Strategy Committee, the Board approves:
- the Amended and Restated Quality Assurance Policy for Pharmaceutical Products as set forth in Annex 1 to GF/B50/05;
- the Amended and Restated Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment, as set forth in Annex 2 to GF/B50/05, which replaces in its entirety the former Quality Assurance Policy for Diagnostics Products; and
- the delegation of authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to the two quality assurance policies referenced above, in line with Annex 3 to GF/B50/05 and to report back to the Strategy Committee and Board on all such changes.
Budgetary Implications
This decision has no budgetary implications.